May 11, 2023
2 min watch
Save
VIDEO: Eyenovia officials discuss approval of Mydcombi ophthalmic spray for mydriasis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- The FDA approved Mydcombi for mydriasis.
- Norbert Lowe and Michael Rowe of Eyenovia demonstrate the spray and discuss its summer release.
SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Norbert Lowe and Michael Rowe of Eyenovia announce the FDA approval of Mydcombi, an ophthalmic spray designed to induce mydriasis.
“It’s actually going to be one of the first and only FDA-approved fixed-dose combination ophthalmic sprays for mydriasis,” Lowe said.
Lowe and Rowe discuss the logistics of the release, planned for this summer, and provide a brief demonstration of how to use the ophthalmic spray.
“It will save people a lot of time. It will be easier for people to use and should make for an overall better experience in pupil dilation,” Rowe said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Lowe reports being the vice president of commercial operations at Eyenovia. Rowe reports being the CEO of Eyenovia.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.